After strong Q1, drug firms' revenue growth to dip to 7%, say analysts

The first quarter (Q1) of this financial year was a strong one for pharmaceutical players, driven by 28 per cent domestic growth on a GST-disrupted base

from Home Page https://ift.tt/2NCjxTW